Colgate-Palmolive delivered a clean beat-and-raise third quarter. Base Business EPS of $0.97 topped the $0.92 consensus by 5.4% and grew 6.6% year over year. Revenue of $5.369 billion beat the $5.33 billion estimate by 0.7% and rose 4.6%. The bigger news was the guidance. Management lifted full-year Base Business EPS growth to 5% to 7% from mid-single digits and moved gross margin guidance to up year over year from roughly flat. That is the third consecutive improvement in the margin outlook, which was guided down at Q1. The central tension is that margins are improving faster than demand. Colgate is extracting more profit from categories that are still growing only modestly, and management said the cost picture gets harder before it gets easier.

The quality of the beat holds up better than many consumer-staples prints. Organic sales rose 3.6%, ahead of the 3.0% nine-month pace. The mix was balanced: 1.7% volume and 2.0% pricing, with a 0.2% drag from the exit from private label pet food. Management highlighted a fourth straight quarter of sequential improvement in worldwide volume growth. Base gross margin expanded 90 basis points to 60.3%. Base operating margin still rose 20 basis points to 20.8%, even though advertising jumped 15% to $775 million. On a GAAP basis, EPS rose only 3% to $0.94 and operating margin slipped 30 basis points. The gap reflects $29 million of Strategic Growth and Productivity Program charges. Those restructuring costs total $327 million year to date, so the GAAP versus non-GAAP gap is real, though it is tied to a defined program.

The call explained how the margin gains were built. Productivity offset roughly 290 basis points of an approximately 300-basis-point materials headwind, and pricing and mix added the rest. Overhead efficiencies reached about 90 basis points of SG&A and have grown every quarter, with more program savings expected through 2028.

The standout operating story was Hill's. Organic growth excluding private label accelerated to 6.5% from 4% in Q2 and 4.8% in Q1. Volume improved to +1.8%, and Prescription Diet Cat grew double digits. The private label drag ends after this quarter, which cleans up Hill's reported growth going forward. One caution: Hill's operating margin dipped 20 basis points as Colgate invested in advertising and the U.S. rollout of fresh single-protein diets.

Latin America was the other engine. Organic sales grew 6.0% and segment operating profit rose 17%, helped by double-digit growth in Brazil. India and Nigeria also grew double digits, and Colgate China grew high single digits.

The soft spots are significant:

• **North America:** Organic sales fell 1.6% on a 3.7% volume decline. Operating profit dropped 11% and segment margin fell 210 basis points. Management described early improvement in U.S. toothpaste share and a restructured go-to-market team. Still, it called the turnaround a work in process, with payoff targeted for 2027.
• **Mexico and other markets:** Mexico slowed on a weak consumer and retailer-specific issues, and management expects another tough fourth quarter. The Middle East faces pricing challenges, and the China category remains soft.
• **Category growth:** Global category growth of roughly 1.5% to 3% is sluggish, with North America the weakest and Europe and pet flat.
• **Breadth:** Organic growth was positive in four of five divisions, down from all five in Q2.

The forward risks give bears legitimate ammunition. Management expects Q4 to bring the year's highest commodity inflation and highest logistics costs, with headwinds persisting into 2027, and offered no 2027 guidance. Raw material inflation is back at about $300 million after Q2 hinted it could come in lower. FX is turning adverse, particularly the Brazilian real, reversing a tailwind cited earlier in the year. Free cash flow before dividends grew 7% year to date to $2.51 billion, a slowdown from the 18% pace through Q2. That did not stop Colgate from returning $2.2 billion to shareholders year to date, and the diluted share count fell about 1.3%.

Investors were not leaning bullish into the print. Earnings Whispers sentiment moved further into negative territory, falling from -0.08 to -0.20, a meaningful but not extreme shift. Price action was more constructive. Shares at $93.16 were 2.5% above the open following the July report and about 4% above the 200-day moving average. The stock had swung sharply within the quarter, rallying from a low of $83.99 on October 2 to a high of $97.50 on October 22, and entered the report 4.5% below that peak. Price-based trend readings are positive, while sequential growth and momentum are neutral, consistent with a stock that has stabilized more than it has re-rated. Skeptical sentiment paired with a stock already up nearly 11% from its quarterly low makes the setup more complicated than the surprise implies.

The bottom line is that Colgate delivered the margin-led beat-and-raise that steady compounders are expected to produce. Accelerating Hill's growth, firmer volumes, and a third straight gross margin upgrade preserve a credible earnings story. However, the drivers are productivity and pricing rather than category demand. North America remains a drag, and Q4 is set to absorb peak cost inflation and adverse currency. The raised outlook earns credit, but the durability of margin gains into 2027 is the question this quarter did not answer.